ArticleFrontiers in immunology2026
Cytokines in cerebrospinal fluid combined with machine learning improve the diagnostic accuracy and predict the progression of neurosyphilis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CSF peptidomics reveals an IGF2-derived peptide as a candidate biomarker for neurosyphilis diagnosis.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Syphilis is a sexually transmitted disease (STD) caused by Methods: From April 2021 to April 2023, 129 patients with syphilis were enrolled and divided into the non-neurosyphilis group (common syphilis, CS, n=19), asymptomatic neurosyphilis group (AN, n=77), symptomatic neurosyphilis group (NS, n=33) and a control group (n=15). Forty-eight cytokines/chemokines in the CSF samples were measured and analysed in combination with clinical indices. Feature selections were further analysed for the using different machine learning model for the diagnosis and progression predicting of neurosyphilis. Results: Machine learning-based feature selection identified a three-cytokine panel (RANTES, MIP-1β, and IL-3) that effectively distinguished syphilis patients from controls (AUC = 0.869, 95% CI: 0.821-0.917). For prediction of symptomatic neurosyphilis progression, IL-2Rα emerged as the optimal standalone biomarker, achieving an AUROC of 0.843 (95% CI: 0.784-0.902) for discriminating asymptomatic from symptomatic disease. Multivariable analysis confirmed IL-2Rα retained independent discriminatory power after adjusting for age (multivariable AUC = 0.876, 95% CI: 0.827-0.925). Age-stratified ROC analysis revealed IL-2Rα maintains robust diagnostic utility across all adult age groups, with optimal Youden-derived cut-offs of 21.82 U/mL (sensitivity 100.0%, specificity 85.7%, AUC 0.939) for 35-45 years; 25.48 U/mL (sensitivity 83.3%, specificity 88.9%, AUC 0.889) for 45-55 years; and 24.54 U/mL (sensitivity 73.7%, specificity 84.6%, AUC 0.789) for >55 years. The combination of IL-2Rα and IP-10 significantly improved predictive accuracy within specific age strata, achieving AUCs of 0.949 (35-45 years), 1.000 (45-55 years), and 0.814 (>55 years) when distinguishing symptomatic from asymptomatic neurosyphilis. Conclusion: In conclusion, IL-2Rα and IP-10 represent promising predictive biomarkers for neurosyphilis progression, with their combined application achieving high diagnostic accuracy for distinguishing symptomatic from asymptomatic disease. These findings establish a foundation for CSF cytokine-guided risk stratification in syphilis patients, although prospective validation in larger, age-matched cohorts is warranted to optimize clinical cut-offs and confirm generalizability across diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.